Trials (Sep 2022)
Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units
- Sharon B. Love,
- Fay Cafferty,
- Claire Snowdon,
- Karen Carty,
- Joshua Savage,
- Philip Pallmann,
- Lucy McParland,
- Louise Brown,
- Lindsey Masters,
- Francesca Schiavone,
- Dominic Hague,
- Stephen Townsend,
- Claire Amos,
- Annabelle South,
- Kate Sturgeon,
- Ruth Langley,
- Timothy Maughan,
- Nicholas James,
- Emma Hall,
- Sarah Kernaghan,
- Judith Bliss,
- Nick Turner,
- Andrew Tutt,
- Christina Yap,
- Charlotte Firth,
- Anthony Kong,
- Hisham Mehanna,
- Colin Watts,
- Robert Hills,
- Ian Thomas,
- Mhairi Copland,
- Sue Bell,
- David Sebag-Montefiore,
- Robert Jones,
- Mahesh K. B. Parmar,
- Matthew R. Sydes
Affiliations
- Sharon B. Love
- MRC Clinical Trials Unit at UCL
- Fay Cafferty
- The Institute of Cancer Research
- Claire Snowdon
- The Institute of Cancer Research
- Karen Carty
- Cancer Research UK Clinical Trials Unit, Level 0 The Beatson West of Scotland Cancer Centre
- Joshua Savage
- Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences, University of Birmingham
- Philip Pallmann
- Centre for Trials Research, Cardiff University
- Lucy McParland
- PHASTAR
- Louise Brown
- MRC Clinical Trials Unit at UCL
- Lindsey Masters
- MRC Clinical Trials Unit at UCL
- Francesca Schiavone
- MRC Clinical Trials Unit at UCL
- Dominic Hague
- MRC Clinical Trials Unit at UCL
- Stephen Townsend
- MRC Clinical Trials Unit at UCL
- Claire Amos
- MRC Clinical Trials Unit at UCL
- Annabelle South
- MRC Clinical Trials Unit at UCL
- Kate Sturgeon
- MRC Clinical Trials Unit at UCL
- Ruth Langley
- MRC Clinical Trials Unit at UCL
- Timothy Maughan
- University of Oxford
- Nicholas James
- The Institute of Cancer Research
- Emma Hall
- The Institute of Cancer Research
- Sarah Kernaghan
- The Institute of Cancer Research
- Judith Bliss
- The Institute of Cancer Research
- Nick Turner
- The Institute of Cancer Research
- Andrew Tutt
- The Institute of Cancer Research
- Christina Yap
- The Institute of Cancer Research
- Charlotte Firth
- Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham
- Anthony Kong
- Comprehensive Cancer Centre, King’s College London, Guy’s Campus, New Hunt’s House
- Hisham Mehanna
- Institute for Head and Neck Studies and Education, University of Birmingham
- Colin Watts
- Institute of Cancer and Genomic Sciences, University of Birmingham
- Robert Hills
- Doll Building, CTSU, Nuffield Department of Population Health, University of Oxford
- Ian Thomas
- Centre for Trials Research, Cardiff University
- Mhairi Copland
- Paul O’Gorman Research Centre, Gartnavel General Hospital
- Sue Bell
- Clinical Trials Research Unit (CTRU), Leeds Institute of Clinical Trials Research, University of Leeds
- David Sebag-Montefiore
- Level 4 Bexley Wing St James Institute of Oncology
- Robert Jones
- Beatson West of Scotland Cancer Centre
- Mahesh K. B. Parmar
- MRC Clinical Trials Unit at UCL
- Matthew R. Sydes
- MRC Clinical Trials Unit at UCL
- DOI
- https://doi.org/10.1186/s13063-022-06680-4
- Journal volume & issue
-
Vol. 23,
no. 1
pp. 1 – 14
Abstract
Abstract Background Late-phase platform protocols (including basket, umbrella, multi-arm multi-stage (MAMS), and master protocols) are generally agreed to be more efficient than traditional two-arm clinical trial designs but are not extensively used. We have gathered the experience of running a number of successful platform protocols together to present some operational recommendations. Methods Representatives of six UK clinical trials units with experience in running late-phase platform protocols attended a 1-day meeting structured to discuss various practical aspects of running these trials. We report and give guidance on operational aspects which are either harder to implement compared to a traditional late-phase trial or are specific to platform protocols. Results We present a list of practical recommendations for trialists intending to design and conduct late-phase platform protocols. Our recommendations cover the entire life cycle of a platform trial: from protocol development, obtaining funding, and trial set-up, to a wide range of operational and regulatory aspects such as staffing, oversight, data handling, and data management, to the reporting of results, with a particular focus on communication with trial participants and stakeholders as well as public and patient involvement. Discussion Platform protocols enable many questions to be answered efficiently to the benefit of patients. Our practical lessons from running platform trials will support trial teams in learning how to run these trials more effectively and efficiently.
Keywords
- Platform protocols
- Trial conduct
- Multi-arm multi-stage trials
- Umbrella trials
- Basket trials
- Stratified medicine